Oncternal Therapeutics Alpha and Beta Analysis
| ONCTDelisted Stock | USD 0.53 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Oncternal Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Oncternal Therapeutics over a specified time horizon. Remember, high Oncternal Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Oncternal Therapeutics' market risk premium analysis include:
Beta 3.07 | Alpha (2.18) | Risk 9.82 | Sharpe Ratio (0.37) | Expected Return (3.64) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Oncternal |
Oncternal Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Oncternal Therapeutics market risk premium is the additional return an investor will receive from holding Oncternal Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Oncternal Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Oncternal Therapeutics' performance over market.| α | -2.18 | β | 3.07 |
Oncternal Therapeutics Fundamentals Vs Peers
Comparing Oncternal Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Oncternal Therapeutics' direct or indirect competition across all of the common fundamentals between Oncternal Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Oncternal Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Oncternal Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Oncternal Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Oncternal Therapeutics to competition |
| Fundamentals | Oncternal Therapeutics | Peer Average |
| Return On Equity | -1.5 | -0.31 |
| Return On Asset | -0.76 | -0.14 |
| Operating Margin | (17.57) % | (5.51) % |
| Current Valuation | (12.83 M) | 16.62 B |
| Shares Outstanding | 2.96 M | 571.82 M |
| Shares Owned By Insiders | 9.23 % | 10.09 % |
| Shares Owned By Institutions | 12.07 % | 39.21 % |
Oncternal Therapeutics Opportunities
Oncternal Therapeutics Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | US Stocks Mixed Producer Prices Increase In August | 09/12/2024 |
2 | Oncternal stock crashes by 60 percent as it lays off staff and scraps trials - Pharmaceutical Technology | 09/13/2024 |
3 | Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 12 Study of ONCT-534 for the Treatment of RR Metastatic Castration-Resistant Prostat... | 10/22/2024 |
4 | ONCT Stock Touches 52-Week Low at 1.03 Amid Market Challenges - Investing.com | 11/13/2024 |
5 | Oncternal announces workforce reduction, executive changes | 11/15/2024 |
6 | Oncternal shares to be delisted from Nasdaq | 11/25/2024 |
About Oncternal Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Oncternal or other delisted stocks. Alpha measures the amount that position in Oncternal Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Oncternal Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Oncternal Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Oncternal Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Oncternal Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Oncternal Therapeutics. Please utilize our Beneish M Score to check the likelihood of Oncternal Therapeutics' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Oncternal Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Oncternal Stock
If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |